Clinical Trial Update: Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety and efficacy of adding Durvalumab with consolidative hypofractionated radiotherapy for residual non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: University of Nebraska | Conditions: Lung Cancer, Carcinoma, Non-Small Cell Lung | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING